Literature DB >> 17241123

Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease.

Todd B Sherer1, Jason R Richardson, Claudia M Testa, Byoung Boo Seo, Alexander V Panov, Takao Yagi, Akemi Matsuno-Yagi, Gary W Miller, J Timothy Greenamyre.   

Abstract

Parkinson's disease (PD) has been linked to mitochondrial dysfunction and pesticide exposure. The pesticide rotenone (ROT) inhibits complex I and reproduces features of PD in animal models, suggesting that environmental agents that inhibit complex I may contribute to PD. We have previously demonstrated that ROT toxicity is dependent upon complex I inhibition and that oxidative stress is the primary mechanism of toxicity. In this study, we examined the in vitro toxicity and mechanism of action of several putative complex I inhibitors that are commonly used as pesticides. The rank order of toxicity of pesticides to neuroblastoma cells was pyridaben > rotenone > fenpyroximate > fenazaquin > tebunfenpyrad. A similar order of potency was observed for reduction of ATP levels and competition for (3)H-dihydrorotenone (DHR) binding to complex I, with the exception of pyridaben (PYR). Neuroblastoma cells stably expressing the ROT-insensitive NADH dehydrogenase of Saccharomyces cerevisiae (NDI1) were resistant to these pesticides, demonstrating the requirement of complex I inhibition for toxicity. We further found that PYR was a more potent inhibitor of mitochondrial respiration and caused more oxidative damage than ROT. The oxidative damage could be attenuated by NDI1 or by the antioxidants alpha-tocopherol and coenzyme Q(10). PYR was also highly toxic to midbrain organotypic slices. These data demonstrate that, in addition to ROT, several commercially used pesticides directly inhibit complex I, cause oxidative damage, and suggest that further study is warranted into environmental agents that inhibit complex I for their potential role in PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17241123      PMCID: PMC8669833          DOI: 10.1111/j.1471-4159.2006.04333.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  49 in total

1.  Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors.

Authors:  He-Jin Lee; Soon Young Shin; Chan Choi; Young Han Lee; Seung-Jae Lee
Journal:  J Biol Chem       Date:  2001-11-27       Impact factor: 5.157

2.  Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats.

Authors:  M Alam; W J Schmidt
Journal:  Behav Brain Res       Date:  2002-10-17       Impact factor: 3.332

3.  Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis.

Authors:  Sampathkumar Krishnan; Eva Y Chi; Stephen J Wood; Brent S Kendrick; Cynthia Li; William Garzon-Rodriguez; Jette Wypych; Theodore W Randolph; Linda O Narhi; Anja Leona Biere; Martin Citron; John F Carpenter
Journal:  Biochemistry       Date:  2003-01-28       Impact factor: 3.162

4.  Mitochondrial complex I deficiency in Parkinson's disease.

Authors:  A H Schapira; J M Cooper; D Dexter; P Jenner; J B Clark; C D Marsden
Journal:  Lancet       Date:  1989-06-03       Impact factor: 79.321

5.  Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease.

Authors:  F Cardellach; M J Martí; J Fernández-Solá; C Marín; J B Hoek; E Tolosa; A Urbano-Márquez
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

6.  Use of the NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae as a possible cure for complex I defects in human cells.

Authors:  B B Seo; J Wang; T R Flotte; T Yagi; A Matsuno-Yagi
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

7.  Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease.

Authors:  N Jha; O Jurma; G Lalli; Y Liu; E H Pettus; J T Greenamyre; R M Liu; H J Forman; J K Andersen
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

8.  Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein.

Authors:  L Ko; N D Mehta; M Farrer; C Easson; J Hussey; S Yen; J Hardy; S H Yen
Journal:  J Neurochem       Date:  2000-12       Impact factor: 5.372

9.  Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.

Authors:  Todd B Sherer; Jin Ho Kim; Ranjita Betarbet; J Timothy Greenamyre
Journal:  Exp Neurol       Date:  2003-01       Impact factor: 5.330

10.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.

Authors:  A Yoritaka; N Hattori; K Uchida; M Tanaka; E R Stadtman; Y Mizuno
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

View more
  105 in total

1.  Solvent exposures and Parkinson disease risk in twins.

Authors:  Samuel M Goldman; Patricia J Quinlan; G Webster Ross; Connie Marras; Cheryl Meng; Grace S Bhudhikanok; Kathleen Comyns; Monica Korell; Anabel R Chade; Meike Kasten; Benjamin Priestley; Kelvin L Chou; Hubert H Fernandez; Franca Cambi; J William Langston; Caroline M Tanner
Journal:  Ann Neurol       Date:  2011-11-14       Impact factor: 10.422

2.  The oxygen free radicals originating from mitochondrial complex I contribute to oxidative brain injury following hypoxia-ischemia in neonatal mice.

Authors:  Zoya V Niatsetskaya; Sergei A Sosunov; Dzmitry Matsiukevich; Irina V Utkina-Sosunova; Veniamin I Ratner; Anatoly A Starkov; Vadim S Ten
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

Review 3.  Developmental neurotoxicity - challenges in the 21st century and in vitro opportunities.

Authors:  Lena Smirnova; Helena T Hogberg; Marcel Leist; Thomas Hartung
Journal:  ALTEX       Date:  2014       Impact factor: 6.043

Review 4.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

5.  Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin.

Authors:  G Martella; P Platania; D Vita; G Sciamanna; D Cuomo; A Tassone; A Tscherter; T Kitada; P Bonsi; J Shen; A Pisani
Journal:  Exp Neurol       Date:  2008-11-21       Impact factor: 5.330

Review 6.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

7.  JNK inhibition of VMAT2 contributes to rotenone-induced oxidative stress and dopamine neuron death.

Authors:  Won-Seok Choi; Hyung-Wook Kim; Zhengui Xia
Journal:  Toxicology       Date:  2014-12-09       Impact factor: 4.221

Review 8.  Mechanism of Gene-Environment Interactions Driving Glial Activation in Parkinson's Diseases.

Authors:  Souvarish Sarkar
Journal:  Curr Environ Health Rep       Date:  2021-05-27

9.  Celastrol from 'Thunder God Vine' protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson's disease.

Authors:  Bong-Suk Choi; Hyool Kim; Hyo Jeong Lee; Kumar Sapkota; Se Eun Park; Seung Kim; Sung-Jun Kim
Journal:  Neurochem Res       Date:  2013-11-09       Impact factor: 3.996

Review 10.  Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases.

Authors:  Carlotta Giorgi; Saverio Marchi; Ines C M Simoes; Ziyu Ren; Giampaolo Morciano; Mariasole Perrone; Paulina Patalas-Krawczyk; Sabine Borchard; Paulina Jędrak; Karolina Pierzynowska; Jędrzej Szymański; David Q Wang; Piero Portincasa; Grzegorz Węgrzyn; Hans Zischka; Pawel Dobrzyn; Massimo Bonora; Jerzy Duszynski; Alessandro Rimessi; Agnieszka Karkucinska-Wieckowska; Agnieszka Dobrzyn; Gyorgy Szabadkai; Barbara Zavan; Paulo J Oliveira; Vilma A Sardao; Paolo Pinton; Mariusz R Wieckowski
Journal:  Int Rev Cell Mol Biol       Date:  2018-06-22       Impact factor: 6.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.